Menadione
FDA-approved product (tablet, oral), marketed as Menadione.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Hemorrhage
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Vitamin k
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Menadione with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
DULCIS (D-dimer and ULtrasonography in Combination Italian Study)
NCT00954395 · start 2008-09
Registered record
- Registry ID
- NCT00954395
- Conditions
- Venous Thromboembolism
- Interventions
- D-dimer
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2012-06
- Enrolment
- 1,100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVenous ThromboembolismInterventionD-dimerPhaseNot recordedRegistry statusCompletedThe Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients
NCT01235325 · start 2008-07
Registered record
- Registry ID
- NCT01235325
- Conditions
- Supplementation; Bone Health; Crohn's Disease
- Interventions
- phylloquinone (vitamin K1); placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2010-11
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSupplementation; Bone Health; Crohn's DiseaseInterventionphylloquinone (vitamin K1); placeboPhasePhase 4Registry statusCompletedPredictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death
NCT01864122 · start 2007-01
Registered record
- Registry ID
- NCT01864122
- Conditions
- Cardiovascular Disease
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2010-10
- Enrolment
- 2,448
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseaseInterventionNot recordedPhaseNot recordedRegistry statusCompletedChanges in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial
NCT00355290 · start 2006-08
Registered record
- Registry ID
- NCT00355290
- Conditions
- Blood Coagulation Disorders
- Interventions
- Changes on Oral Vitamin K Intake
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2007-12
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBlood Coagulation DisordersInterventionChanges on Oral Vitamin K IntakePhaseNot applicableRegistry statusCompletedEffect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
NCT00183001 · start 2001-10
Registered record
- Registry ID
- NCT00183001
- Conditions
- Osteoporosis; Vascular Calcification; Inflammation
- Interventions
- Vitamin K
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-10
- Completion
- 2006-10
- Enrolment
- 452
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosis; Vascular Calcification; InflammationInterventionVitamin KPhasePhase 3Registry statusCompleted